Jordyn Sava is an editor for Targeted Oncology.
High-Dose Anakinra Shows Promise in Treating CRS/ICANS Post CAR T-Cell Therapy
May 18th 2022In an interview with Targeted Oncology, Nicolas Gazeau, further discusses his analysis of anakinra when administered at 2 different dose regimens for patients with refractory CRS/ICANS after CAR T-cell therapy.
Antibiotic De-Escalation is Well-Tolerated in AML With Febrile and Prolonged Neutropenia
May 17th 2022Having an antibiotic de-escalation guideline did not affect the rate of bacterial infection after antibiotic de-escalation, all cause-mortality, or hospital length of stay in patients with acute myeloid leukemia and febrile neutropenia who were clinically stable and afebrile.
Endocrine Therapy Plus Bevacizumab Shows Benefit in ER+/HER2- Breast Cancer
May 12th 2022Endocrine therapy plus bevacizumab with the possibility of weekly paclitaxel reinduction signals efficacy and demonstrates a good safety profile in patients with ER-positive, HER2-negative advanced or metastatic breast cancer who have responded to induction therapy.
Positive Survival Outcomes With/ Without Paclitaxel in Patients With HER2+ Breast Cancer
May 5th 2022Survival rates for patients with different subtypes of early breast cancer who had a pathological complete response after de-escalated 12-week trastuzumab plus pertuzumab with or without weekly paclitaxel are promising.
Ribociclib Demonstrates Promising OS Benefit in HR+/HER2- Advanced Breast Cancer
May 4th 2022Combination of ribociclib plus fulvestrant achieved a median overall survival of 67.6 months in the first-line setting for patients with postmenopausal, hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.
Dosing of KIN-3248 Begins in Advanced Solid Tumors With FGFR2 and/or FGFR3 Alterations
May 2nd 2022The first patient has been dosed in the phase 1 KN-4802 trial examining the safety, tolerability, and preliminary efficacy of KIN-3248 in adult patients with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations.
Larotrectinib Efficacy Withstands Various NTRK Gene Fusions in Non-Primary CNS TRK Fusion+ Cancer
May 1st 2022In an interview with Targeted Oncology, Marc Ladanyi, MD, discussed pooled data of larotrectinib in patients with NTRK fusion-positive cancers and how variability in NTRK gene fusions impacts outcomes.